Supernus Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system disorders, particularly in the United States. Based in Rockville, Maryland, Supernus specializes in addressing unmet medical needs in epilepsy and migraine, supported by a promising pipeline aimed at improving patient outcomes. With a commitment to enhancing quality of life for affected individuals, the company operates in a rapidly expanding market, presenting substantial growth opportunities for institutional investors.